(Q50910994)

English

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

scientific article published on 21 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

0 references

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

Bayesian network

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Sang-Cheol Bae

2

0 references

author name string

Young Ho Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

Gwan Gyu Song

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

publication date

21 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

Rheumatology International

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

35

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

12

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

1965-1974

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

https://scigraph.springernature.com/pub.10.1007/s00296-015-3291-4

0 references

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Janus kinases in immune cell signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Tofacitinib for rheumatoid arthritis - Authors' reply

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Network meta-analysis for comparing treatment effects of multiple interventions: an introduction

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

A Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-015-3291-4

21 January 2018

PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FDA approves tofacitinib for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genome scan meta-analysis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Automating network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25994093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-015-3291-4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/25994093

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50910994&oldid=1567998974"